1-12 of 12
daratumumab
Close
Sort by
Journal Articles

Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma

Christie P. M. Verkleij, Marloes E. C. Broekmans, Mark van Duin, Kristine A. Frerichs, Rowan Kuiper, A. Vera de Jonge, Martin Kaiser, Gareth Morgan, Amy Axel, Rengasamy Boominathan, Jocelyn Sendecki, Amy Wong, Raluca I. Verona, Pieter Sonneveld, Sonja Zweegman, Homer C. Adams, III, Tuna Mutis, Niels W. C. J. van de Donk
Journal: Blood Advances
Blood Adv (2021) 5 (8): 2196–2215.
https://doi.org/10.1182/bloodadvances.2020003805
Published: 2021
Includes: Supplemental data
Journal Articles

Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma

Hilma J. van der Horst, Anne T. Gelderloos, Martine E. D. Chamuleau, Esther C. W. Breij, Sonja Zweegman, Inger S. Nijhof, Marije B. Overdijk, Tuna Mutis
Journal: Blood Advances
Blood Adv (2021) 5 (8): 2165–2172.
https://doi.org/10.1182/bloodadvances.2020003731
Published: 2021
Includes: Supplemental data
Journal Articles

Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN

Clinical Trials & Observations
Peter M. Voorhees, Cesar Rodriguez, Brandi Reeves, Nitya Nathwani, Luciano J. Costa, Yana Lutska, Padma Bobba, Daniela Hoehn, Huiling Pei, Jon Ukropec, Ming Qi, Thomas S. Lin, Paul G. Richardson
Journal: Blood Advances
Blood Adv (2021) 5 (4): 1092–1096.
https://doi.org/10.1182/bloodadvances.2020003642
Published: 2021
Journal Articles

Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8 + T-cell responses

Alak Manna, Timothy Kellett, Sonikpreet Aulakh, Laura J. Lewis-Tuffin, Navnita Dutta, Keith Knutson, Eduardo Chini, Javier Pinilla-Ibarz, Nicole Lamanna, Rami Manochakian, Fabio Malavasi, Taimur Sher, Asher A. Chanan-Khan, Sikander Ailawadhi, Aneel Paulus
Journal: Blood Advances
Blood Adv (2020) 4 (10): 2143–2157.
https://doi.org/10.1182/bloodadvances.2019001091
Published: 2020
Includes: Supplemental data
Journal Articles

Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression

Clinical Trials & Observations
Zachary J. Walker, Michael J. VanWyngarden, Brett M. Stevens, Diana Abbott, Andrew Hammes, Christophe Langouët-Astrie, Clayton A. Smith, Brent E. Palmer, Peter A. Forsberg, Tomer M. Mark, Craig T. Jordan, Daniel W. Sherbenou
Journal: Blood Advances
Blood Adv (2020) 4 (8): 1628–1639.
https://doi.org/10.1182/bloodadvances.2019000122
Published: 2020
Includes: Supplemental data
Journal Articles

Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function

Clinical Trials & Observations
Paolo Milani, Marco Basset, Paola Curci, Andrea Foli, Rita Rizzi, Mario Nuvolone, Raffaella Guido, Loreto Gesualdo, Giorgina Specchia, Giampaolo Merlini, Giovanni Palladini
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1321–1324.
https://doi.org/10.1182/bloodadvances.2020001553
Published: 2020
Includes: Supplemental data
Journal Articles

Successful treatment of thrombocytopenia with daratumumab after allogeneic transplant: a case report and literature review

Clinical Trials & Observations
Yazan Migdady, Asiri Ediriwickrema, Ryan Patrick Jackson, Wendy Kadi, Ridhi Gupta, Francisco Socola, Sally Arai, Beth A. Martin
Journal: Blood Advances
Blood Adv (2020) 4 (5): 815–818.
https://doi.org/10.1182/bloodadvances.2019001215
Published: 2020
Journal Articles

Organ responses with daratumumab therapy in previously treated AL amyloidosis

Clinical Trials & Observations
Alfred Chung, Gregory P. Kaufman, Surbhi Sidana, Erik Eckhert, Stanley L. Schrier, Richard A. Lafayette, Sally Arai, Ronald M. Witteles, Michaela Liedtke
Journal: Blood Advances
Blood Adv (2020) 4 (3): 458–466.
https://doi.org/10.1182/bloodadvances.2019000776
Published: 2020
Journal Articles

CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study

Clinical Trials & Observations
M. O’Dwyer, R. Henderson, S. D. Naicker, M. R. Cahill, P. Murphy, V. Mykytiv, J. Quinn, C. McEllistrim, J. Krawczyk, J. Walsh, E. Lenihan, T. Kenny, A. Hernando, G. Hirakata, I. Parker, E. Kinsella, G. Gannon, A. Natoni, K. Lynch, A. E. Ryan
Journal: Blood Advances
Blood Adv (2019) 3 (12): 1815–1825.
https://doi.org/10.1182/bloodadvances.2019000010
Published: 2019
Includes: Supplemental data
Journal Articles

Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation

Clinical Trials & Observations
Catharina Schuetz, Manfred Hoenig, Despina Moshous, Christof Weinstock, Martin Castelle, Matthieu Bendavid, Kristin Shimano, Vanessa Tolbert, Ansgar S. Schulz, Christopher C. Dvorak
Journal: Blood Advances
Blood Adv (2018) 2 (19): 2550–2553.
https://doi.org/10.1182/bloodadvances.2018020883
Published: 2018
Journal Articles

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma

Clinical Trials & Observations
Tineke Casneuf, Xu Steven Xu, Homer C. Adams, III, Amy E. Axel, Christopher Chiu, Imran Khan, Tahamtan Ahmadi, Xiaoyu Yan, Sagar Lonial, Torben Plesner, Henk M. Lokhorst, Niels W. C. J. van de Donk, Pamela L. Clemens, A. Kate Sasser
Journal: Blood Advances
Blood Adv (2017) 1 (23): 2105–2114.
https://doi.org/10.1182/bloodadvances.2017006866
Published: 2017
Includes: Supplemental data
Journal Articles

Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients

Cirino Botta, Domenico Ciliberto, Marco Rossi, Nicoletta Staropoli, Maria Cucè, Teresa Galeano, Pierosandro Tagliaferri, Pierfrancesco Tassone
Journal: Blood Advances
Blood Adv (2017) 1 (7): 455–466.
https://doi.org/10.1182/bloodadvances.2016003905
Published: 2017
Includes: Supplemental data